Holen Sie sich die Stockscreener-App
11.93
0.91%
-0.1257
Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 6.4%Should You Sell? - MarketBeat
Buyback Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stock2026 Retail Activity & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Armata Pharmaceuticals Inc currently under institutional pressureWeekly Profit Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Earnings Beat: Is Armata Pharmaceuticals Inc currently under institutional pressure2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
ARMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Update Recap: What analysts say about Armata Pharmaceuticals Inc stockEarnings Risk Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Armata Pharmaceuticals, Inc. (TG1N.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - The Globe and Mail
Armata Pharmaceuticals schedules annual meeting for June 11 - Investing.com
Armata Pharmaceuticals schedules annual meeting for June 11 By Investing.com - Investing.com India
Armata Pharmaceuticals sets June 11, 2026 for annual stockholders meeting - TradingView — Track All Markets
ARMP Technical Analysis & Stock Price Forecast - Intellectia AI
Market Outlook: Is Armata Pharmaceuticals Inc stock a smart retirement pick2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Innoviva (INVA) files 10-K/A adding Armata audited financials and new officer certifications - stocktitan.net
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss By Investing.com - Investing.com Australia
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss - Investing.com
Armata Pharmaceuticals Reports $173.8 Million Net Loss for 2025 Amid Convertible Loan Impact and Impairment Charges - Minichart
ARMP Reports Decrease in Grant Revenue for Q4 2025 - GuruFocus
Armata Pharmaceuticals: Advancing Bacteriophage Therapies for Antibiotic-Resistant Bacterial Infections in 2025 - Minichart
Armata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
Breakout Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stockPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
ARMATA PHARMACEUTICALS, INC._December 31, 2025 - SEC.gov
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - Finviz
Armata Pharmaceuticals (NASDAQ: ARMP) advances late-stage phage pipeline with new funding - Stock Titan
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ARMP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Armata Pharmaceuticals Reports Positive Phase 2a Study Results - MSN
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval By Investing.com - Investing.com India
Armata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update - marketscreener.com
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval - Investing.com
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - Finviz
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay - tipranks.com
Armata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
Armata Pharmaceuticals (ARMP) delays 2025 results, advances AP-SA02 toward Phase 3 - Stock Titan
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
Armata Pharmaceuticals (ARMP) CBO reports tax-withheld share disposition - Stock Titan
Armata (ARMP) CEO Birx has 4,919 RSU shares withheld for tax obligations - Stock Titan
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant - Stock Titan
Armata (NASDAQ: ARMP) director receives 25,640 stock options at $11.61 strike - Stock Titan
[Form 4] Armata Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Armata Pharmaceuticals (ARMP) director granted 25,640 stock options - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
New Strong Sell Stocks for April 24th - MSN
Will Armata Pharmaceuticals Inc. stock outperform growth indexesQuarterly Portfolio Summary & Verified Technical Trade Signals - Naître et grandir
1.04%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):